Company Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Stephane Bancel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5800
Contact Information
- Website
- https://www.modernatx.com
- Address
- 200 Technology Square
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 10.29B market capitalization
- Trading Volume: 1.11M shares traded today
- Price Range: 52-week range of $23.15 - $91.99
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Moderna, Inc.
Moderna, Inc. (MRNA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 10.29B, the company represents a significant player in its market. The stock is currently trading at $26.44 with a negativedaily change of 0.64%.
The company's 5800 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -3.52, beta of 1.83, and 52-week price range from $23.15 to $91.99when evaluating investment opportunities.
Why Invest in Moderna, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Stephane Bancel
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.